Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis.
Department of Internal Medicine, Icahn School of Medicine at Mount Sinai St' Luke and Mount Sinai West, Tenth Avenue, Suite 3A-09, New York, NY, 10019, USA. Chayakrit.Krittanawong@mountsinai.org.|Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. Chayakrit.Krittanawong@mountsinai.org.
Chayakrit
C
Krittanawong
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
Takeshi
T
Kitai
Division of Cardiovascular Disease, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
HongJu
H
Zhang
Division of Cardiovascular Disease, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Tao
T
Sun
D006801:Humans; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D000091362:PCSK9 Inhibitors; D015201:Meta-Analysis as Topic; D000078202:Systematic Reviews as Topic; D000071449:Proprotein Convertase 9
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C577155:evolocumab; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9